Akebia Therapeutics (Nasdaq: AKBA) granted stock options to two newly hired employees on July 31, 2026, covering an aggregate 61,000 shares of common stock as inducement awards under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.32 per share, equal to the closing price on the grant date.
The options vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting quarterly thereafter, subject to continued service. Each option has a 10-year term and is granted under Akebia’s inducement award program and a related stock option agreement.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Explained
Akebia granted options covering 61,000 common shares, creating potential—not current—additional share issuance for existing holders; vesting is spread over four years and remains subject to continued employee service.
Market Context
Historical inducement-grant records show contrasting 24-hour moves of +4.84% and -8.2%. The announce...
Analysis
Historical inducement-grant records show contrasting 24-hour moves of +4.84% and -8.2%. The announcement adds compensation structure, while Net Selling insider activity remains a sourced risk to monitor.
Key Figures
Employees receiving grants:2 employeesShares covered:61,000 sharesGrant date:July 31, 2026+5 more
"The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
inducementfinancial
"The options were granted as an inducement material to each employee entering"
Something offered to persuade someone to act a certain way, such as a payment, gift, rebate, stock award, or other benefit intended to influence decisions. Investors care because inducements can change behavior inside or around a company—affecting costs, sales practices, or management incentives—and can create conflicts of interest or trigger regulatory review. Think of it like a coupon or bonus meant to sway a choice, which can alter expected outcomes for shareholders.
vestingfinancial
"The stock options vest over four years, with 25% of the shares vesting"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
exercise pricefinancial
"The options have an exercise price of $1.32 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 2 newly-hired employees options to purchase an aggregate of 61,000 shares of Akebia’s common stock on July 31, 2026. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $1.32 per share, which is equal to the closing price of Akebia’s common stock on the grant date.The stock options vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee’s continued service with Akebia.Each stock option has a 10-year term and is subject to the terms and conditions of Akebia’s inducement award program and a stock option agreement covering the grant.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
What inducement stock options did Akebia Therapeutics (AKBA) grant on July 31, 2026?
Akebia Therapeutics granted options for an aggregate 61,000 shares to two newly hired employees on July 31, 2026. According to Akebia, these options are inducement awards granted under Nasdaq Listing Rule 5635(c)(4) in connection with the employees entering into employment with the company.
What is the exercise price of the new Akebia Therapeutics (AKBA) inducement options?
The exercise price of the new Akebia Therapeutics inducement options is $1.32 per share. According to Akebia, this price equals the closing price of its common stock on the July 31, 2026 grant date, aligning the award terms with the market price at issuance.
How do the Akebia Therapeutics (AKBA) inducement options granted in July 2026 vest?
The Akebia Therapeutics inducement options vest over four years. According to Akebia, 25% of the shares vest on the first anniversary of the grant date, and the remaining 75% vest quarterly thereafter, subject to each new employee’s continued service with the company.
What is the term of the Akebia Therapeutics (AKBA) inducement stock options granted in 2026?
Each Akebia Therapeutics inducement stock option granted on July 31, 2026 has a 10-year term. According to Akebia, the options are also subject to the company’s inducement award program and an individual stock option agreement governing the grant terms.
Why did Akebia Therapeutics (AKBA) use Nasdaq Listing Rule 5635(c)(4) for these option grants?
Akebia used Nasdaq Listing Rule 5635(c)(4) because the options were granted as inducement awards material to employment. According to Akebia, the grants were made to two newly hired employees specifically in connection with their agreements to join the company.
How many employees received Akebia Therapeutics (AKBA) inducement options in July 2026 and how many shares are covered?
Two newly hired employees received the inducement option grants in July 2026. According to Akebia, these options collectively cover an aggregate of 61,000 shares of the company’s common stock, granted as part of its inducement award program.
